Kaleido Biosciences, Inc. (KLDO) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Lexington, MA, 美国. 现任CEO为 Mark A. Wingertzahn.
KLDO 拥有 IPO日期为 2019-02-28, 76 名全职员工, 在 Other OTC, 市值为 $4.26K.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
